Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2002
06/04/2002US6399371 Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
06/04/2002US6399370 Compositions and methods for use of defensin
06/04/2002US6399369 Multipotent neural stem cell cDNA libraries
06/04/2002US6399348 DNA sequences for matrix metalloproteases, their production and use
06/04/2002US6399345 Subunits of NADH dehydrogenase
06/04/2002US6399343 Amino acid sequence of gene from streptococcus; drug screening for bactericides
06/04/2002US6399333 Process for producing erythropoietin containing no animal proteins
06/04/2002US6399328 Amino acid sequence; hybridization probes; amplification primers; anticarcinogenic agents; antitumor agents
06/04/2002US6399327 Dna sequence which codes for specific amino acid sequence of a polypeptide capable of binding to mort-1 which in turn binds to intracellular domain of fas receptor
06/04/2002US6399326 Nucleic acid which encodes polypeptide of defined amino acid sequence which has a cysteine motif
06/04/2002US6399322 Identifying proteins from t helper 2 cells that interact with maf family proteins using indicator cells with reporter gene linked to a transcriptional regulatory sequence which binds maf family proteins
06/04/2002US6399316 PACAP receptor protein, method for preparing said protein, and use thereof
06/04/2002US6399315 Drug screening by contacting cells transfected with nucleic acid encoding a g-protein coupled receptor which binds corticotropin-releasing factor, then monitoring cell for compounds which bind the receptor
06/04/2002US6399301 Amino acid sequence; diagnosis of cancer and inflammation; antiinflammatory agents; anticarcinogenic agents
06/04/2002US6399294 Probes; primers; immunogens; for diagnosis of human immunodeficiency virus infections
06/04/2002US6399114 Nutritional system for nervous system disorders
06/04/2002US6399103 Dispersing physiologically active polypeptide into biodegradable polymer and zinc oxide; high entrapment ratio; high blood concentration levels over extended period
06/04/2002US6399101 Levothyroxine sodium and silicified microcrystalline cellulose; tablets; light, heat, and humidity stable
06/04/2002US6399098 Composition for treating dental caries caused by streptococcus mutans
06/04/2002US6399097 Composition for treatment of a bacterial infection of the digestive tract
06/04/2002US6399090 Insulin supplemented infant formula
06/04/2002US6399079 Spill resistant pharmaceutical compositions in semi-solid form
06/04/2002US6399078 Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
06/04/2002US6399075 Peptide sequences for viricides
06/04/2002US6399071 Removal of xenobodies from body fluid
06/04/2002US6399070 Heat shock protein complex for immunology
06/04/2002US6399069 Purification and prevention of disease with heat shock protein bound to antigens
06/04/2002US6399068 Cancer treatment, interleukins, fusion proteins, cell markers
06/04/2002US6399067 Methods and compositions for impairing multiplication of HIV-1
06/04/2002US6399066 Capsular polysaccharide adhesin antigen, preparation, purification and use
06/04/2002US6399065 Methods for modulating SLAM-expressing T cells
06/04/2002US6399064 Cloning endothelial cells and protein c
06/04/2002US6399063 Monoclonal antibodies directed to the HER2 receptor
06/04/2002US6399061 Monoclonal secreted by atcc deposit no. hb11388 and transfectoma tcae8 accorded atcc deposit no. 69119; parenteral injection
06/04/2002US6399059 Thermally stable enzyme composition and method of preparing the same
06/04/2002US6399058 Methods for treating ocular diseases
06/04/2002US6399053 Methods of enhancing bioactivity of chemokines
06/04/2002US6398816 Genetic engineering of cells to enhance healing and tissue regeneration
06/04/2002US6398757 Gene therapeutic treatment of blood vessel associated disorders
06/04/2002US6397849 Methods of ophthalmic administration
06/04/2002CA2361950A1 Antibiotics g 23077, pharmaceutically acceptable salts and compositions, and use thereof
06/04/2002CA2205198C Human neutrophil elastase inhibitors
06/04/2002CA2174097C Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
06/04/2002CA2171424C Acylated insulin
06/04/2002CA2119262C Compositions comprising a bactericidal/permeability increasing protein and a lipid carrier, methods of making same, and uses thereof
06/04/2002CA2078990C Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
06/04/2002CA2076593C Polypeptides and use thereof
06/04/2002CA1341364C Single polypeptide chain binding molecules
06/03/2002WO2002000202A1 Endoparasiticidal agents for voluntary oral ingestion by animals
06/01/2002CA2325666A1 Immunogenic mutated peptides derived from r9m, polynucleotides, coding polynucleotides and their therapeutic uses
05/2002
05/30/2002WO2002042777A2 Modulation of the interaction between evh1 domains
05/30/2002WO2002042776A2 Compositions and methods relating to prostate specific genes and proteins
05/30/2002WO2002042772A1 TRIPEPTIDE OF FCηRIIA
05/30/2002WO2002042489A1 Methods involving a t cell protein tyrosine phosphatase
05/30/2002WO2002042462A2 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
05/30/2002WO2002042460A2 Compositions and methods relating to colon specific genes and proteins
05/30/2002WO2002042458A2 G protein coupled receptors
05/30/2002WO2002042457A1 Cloning and expression of human slap-2: a novel sh2/sh3 domain-containing human slap homologue having immune cell-specific expression
05/30/2002WO2002042456A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/30/2002WO2002042455A2 Modifier of organelle metalbolism
05/30/2002WO2002042453A1 A novel polypeptide, a human big protein 0767-19.36 and the polynucleotide encoding the polypeptide
05/30/2002WO2002042452A2 Adapter protein and gene encoding it
05/30/2002WO2002042449A2 Method for selecting peptide ligands
05/30/2002WO2002042448A1 Novel polypeptide
05/30/2002WO2002042445A2 Differentiated cells suitable for human therapy
05/30/2002WO2002042444A2 Fungal gene cluster associated with pathogenesis
05/30/2002WO2002042441A2 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
05/30/2002WO2002042439A2 Aggrecanase adamts9
05/30/2002WO2002042438A2 Human kinases and polynucleotides encoding the same
05/30/2002WO2002042437A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
05/30/2002WO2002042436A2 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
05/30/2002WO2002042435A2 Regulation of human tyrosine phosphatase
05/30/2002WO2002042425A2 Antisense modulation of mp-1 expression
05/30/2002WO2002042423A2 Antisense modulation of src-2 expression
05/30/2002WO2002042422A2 Molecular interactions in hematopoietic cells
05/30/2002WO2002042420A2 Modulation of gene expression during intimal hyperplasia of the carotid artery
05/30/2002WO2002042415A2 Agents for blocking t cell mediated immune reactions
05/30/2002WO2002042414A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
05/30/2002WO2002042413A2 Methods and compositions involved in groucho-mediated differentiation
05/30/2002WO2002042412A2 Protease inhibitors and their pharmaceutical uses
05/30/2002WO2002042336A2 Fgf-affinity chromatography
05/30/2002WO2002042332A2 Truncated cd200
05/30/2002WO2002042331A1 Basic fibroblastic growth factor with a specific collagen binding domain
05/30/2002WO2002042330A2 Cystoskeleton-associated proteins
05/30/2002WO2002042329A2 Compositions and methods relating to prostate specific genes and proteins
05/30/2002WO2002042327A2 Cocoa albumin and its use in the production of cocoa and chocolate flavour
05/30/2002WO2002042321A2 Mixed fibrils
05/30/2002WO2002042316A2 Pna analogues
05/30/2002WO2002042295A2 Peptides as met-ap2 inhibitors
05/30/2002WO2002042278A2 Imidazole and benzimidazole caspase inhibitors and uses thereof
05/30/2002WO2002042118A2 Oil maintenance indicator
05/30/2002WO2002041922A1 Method of regulating the activity of expression product of gene transferred into living body
05/30/2002WO2002041912A1 Drugs and foods improving the quality of life and process for producing the same
05/30/2002WO2002041911A2 Use of fgf-19 for inhibiting angiogenesis
05/30/2002WO2002041910A2 Methods and compositions for the treatment of diseases of the eye
05/30/2002WO2002041901A1 Treatment of osteoporosis
05/30/2002WO2002041859A1 Use of cyclosporin a 7-thioamide derivatives for hair growth
05/30/2002WO2002041858A1 Use of cyclosporin 7-thioamide derivatives for hair growth
05/30/2002WO2002041837A2 Treatment of mucositis
05/30/2002WO2002041836A2 Antisense modulation of src-1 expression